Abstract:Background: Alzheimer's disease (AD), is a progressive neurodegenerative disease that is characterized by cognitive loss. Most researchers believe that aggregation and accumulation of β-amyloid peptides (Aβ) in brain cells are the central pathological hallmark of this disease. Methods: Based on the amyloid hypothesis, a 10 amino acids β-sheet breaker peptide HPYD (His-Lys-Gln-Leu-Pro-Phe-Tyr-Glu-Glu-Asp) was designed according to the structure and sequence of the previous designed peptide H102. Accelerated stability test, thioflavine T (ThT) fluorescence spectral analysis and transmission electron microscopy (TEM) imaging were performed to detect the stability and inhibitory effects on the aggregation of Aβ1-42 by H102 and HPYD. FITC-labeled HPYD was first tested to determine whether it could be transferred along the olfactory pathway to the brain after nasal administration to mice. Subsequently, the Morris Water Maze (MWM) test for behavioral analysis was used to investigate the learning and memory ability of APP/PS1 transgenic mice by HPYD. Immunohistochemistry and western blot analysis was performed to determine the role of HPYD on Aβ and APP protein levels. In addition, microarray analysis was used to evaluate the effect of HPYD on gene expression in AD mouse models. Results: Our in vitro results demonstrated that HPYD had enhanced stability and inhibitory effects on Aβ1-42 aggregation compared to H102. HPYD could be delivered into the brain through nasal administration and improved the learning and memory ability in APP/PS1 transgenic mouse models by reducing Aβ and APP protein levels. In addition, microarray analyses suggested that several genes related to the inflammatory pathway, AD and gluco-lipid metabolism were dysregulated and could be restored to almost normal levels after HPYD administration to mice. Conclusions: Our results demonstrated that HPYD could be a potential therapeutic drug candidate for the treatment of AD.

PMS777, a New Cholinesterase Inhibitor with Anti-Platelet Activated Factor Activity, Regulates Amyloid Precursor Protein Processing In Vitro

Protection of PMS777, a New AChE Inhibitor with PAF Antagonism, Against Amyloid-β-Induced Neuronal Apoptosis and Neuroinflammation

Pharmacological Profile of Pms777, A New Ache Inhibitor with Paf Antagonistic Activity

PMS777, A Bis-interacting Ligand for PAF Receptor Antagonism and AChE Inhibition, Attenuates PAF-induced Neurocytotoxicity in SH-SY5Y Cells

New Protein Kinase C Activator Regulates Amyloid Precursor Protein Processing In Vitro By Increasing Alpha-Secretase Activity

New protein kinase C activator regulates amyloid precursor protein processing in vitro by increasing α-secretase activity: New PKC activator increases α-secretase activity

Differential effect of PMS777, a new type of acetylcholinesterase inhibitor, and galanthamine on oxidative injury induced in human neuroblastoma SK-N-SH cells

A Novel Rhamnoside Derivative PL402 Up-Regulates Matrix Metalloproteinase 3/9 to Promote Aβ Degradation and Alleviates Alzheimer’s-like Pathology

A New Chiral Pyrrolyl Alpha-Nitronyl Nitroxide Radical Attenuates Beta-Amyloid Deposition And Rescues Memory Deficits In A Mouse Model Of Alzheimer Disease

Novel Piperazine Derivative PMS1339 Exhibits Tri-Functional Properties and Cognitive Improvement in Mice

Mitogen activated protein kinase and protein kinase C activation mediate promotion of sAPPalpha secretion by deprenyl.

DL0410 can reverse cognitive impairment, synaptic loss and reduce plaque load in APP/PS1 transgenic mice

Modulation of the Aβ-Peptide-Aggregation Pathway by Active Compounds From Platycladus orientalis Seed Extract in Alzheimer's Disease Models

Modulation of the Aβ-Peptide-Aggregation Pathway by Active Compounds From Platycladus orientalis Seed Extract in Alzheimer’s Disease Models

β-Sheet Breaker Peptide-HPYD for the Treatment of Alzheimer's Disease: Primary Studies on Behavioral Test and Transcriptional Profiling

Inhibiting Aβ Toxicity in Alzheimer's Disease by a Pyridine Amine Derivative.

Therapeutic Approaches to Alzheimer'S Disease Through Stimulating of Non-Amyloidogenic Processing of Amyloid Precursor Protein

The PARF Antagonist AChE Inhibitor PMS777 Attenuates LPS-Induced Acute Neuroinflammation

Aspartic Acid-Modified Phospholipids Regulate Cell Response and Rescue Memory Deficits in APP/PS1 Transgenic Mice

P4‐687: SUBSTRATE BINDING INHIBITS Γ‐secretase CLEAVAGE OF AMYLOID PRECURSOR PROTEIN

A Polyaminobiaryl-Based β-secretase Modulator Alleviates Cognitive Impairments, Amyloid Load, Astrogliosis, and Neuroinflammation in APPSwe/PSEN1ΔE9 Mice Model of Amyloid Pathology